Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers

被引:0
|
作者
Sarkar, S
Jülicher, KP
Burger, MS
Della Valle, V
Larsen, CJ
Yeager, TR
Grossman, TB
Nickells, RW
Protzel, C
Jarrard, DF
Reznikoff, CA
机构
[1] Univ Wisconsin, Dept Human Oncol, Madison, WI 53792 USA
[2] Univ Wisconsin, Dept Surg, Madison, WI 53792 USA
[3] Univ Wisconsin, Dept Ophthalmol, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med, Madison, WI 53792 USA
[5] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA
[6] Inst Genet Mol, INSERM, U434, F-75010 Paris, France
[7] Fac Sci Poitiers, F-86100 Poitiers, France
[8] Childrens Med Res Inst, Canc Res Unit, Wentworthville, NSW 2145, Australia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of both the pRb (pRb-cyclin D1/cyclin-dependent kinase 4/6-p16) and p53 (p53-p21(WAF1)-p14(ARF)) pathways is thought to be essential for immortalization in vitro and malignant transformation in vivo. We identified different combinations of pRb and p53 pathway alterations in 12 invasive transitional cell carcinomas (TCCs) and addressed the functional significance of the different combinations observed. Results showed four combinations of alterations including -pRb/-p53 (i.e., pRb inactivated in the pRb pathway and p53 inactivated in the p53 pathway; four TCCs), -p16/-p53 (four TCCs), -p16/-p21(WAF1) (one TCC), and -p16/-p14(ARF) (two TCCs), These groups include two new combinations (i.e., -p16/-p53 and -p16/-p21(WAF1)) not reported previously for TCCs, An alteration in the key components of the p53 pathway was not detected in one invasive TCC that had inactivated p16, Note that all four TCCs with inactivated pRb had mutant p53; thus, the combinations of -pRb/-p21(WAF1) and -pRb/-p14(ARF) were not observed. Only two of eight TCCs with altered p16 had concomitant p14(ARF) loss, demonstrating that simultaneous inactivation of these two 9p21INK4a tumor suppressor genes is not obligatory. To determine the biological phenotypes of TCCs with different combinations of pRb and p53 pathway alterations, their downstream responses to gamma radiation were studied in vitro. As expected, none of eight TCCs with mutant p53 responded to gamma radiation by elevation of p53, p21(WAF1), or mdm2 or by cell cycle arrest. Only two of four TCCs with wild-type p53 and wild-type pRb (the combination of -p16/-p14(ARF)) showed normal downstream responses to gamma radiation and underwent cell cycle arrest, Two TCCs with wild-type pRb and wild-type p53 (the combination of -p16/-p21(WAF1) and one TCC with -p16) failed to show cell cycle arrest in response to radiation. This was attributed to the absence of p21(WAF1) in one TCC. In summary, these data support a model of invasive bladder cancer pathogenesis in which both the pRb and p53 pathways are usually inactivated and the biology of the tumor is impacted by the mechanism of their inactivations.
引用
收藏
页码:3862 / 3871
页数:10
相关论文
共 50 条
  • [1] Alterations of the p53 and pRB pathways in human astrocytoma.
    Rutka J.T.
    Akiyama Y.
    Lee S.P.
    Ivanchuk S.
    Tsugu A.
    Hamel P.A.
    Brain Tumor Pathology, 2000, 17 (2) : 65 - 70
  • [2] Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer
    Mathew, R
    Arora, S
    Khanna, R
    Mathur, M
    Shukla, NK
    Ralhan, R
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (06) : 832 - 841
  • [3] Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers
    Singh, A
    Jones, RF
    Friedman, H
    Hathir, S
    Soos, G
    Zabo, A
    Haas, GP
    ANTICANCER RESEARCH, 1999, 19 (6B) : 5415 - 5417
  • [4] Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors
    CordonCardo, C
    Zhang, ZF
    Dalbagni, G
    Drobnjak, M
    Charytonowicz, E
    Hu, SX
    Xu, HJ
    Reuter, VE
    Benedict, WF
    CANCER RESEARCH, 1997, 57 (07) : 1217 - 1221
  • [5] p53 protein accumulation and p53 gene alterations (RFLP, VNTR and p53 gene mutations) in non-invasive versus invasive human transitional bladder cancer
    Shipman, R
    Schraml, P
    Moch, H
    Colombi, M
    Sauter, G
    Mihatsch, MJ
    Ludwig, CU
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 10 (04) : 801 - 806
  • [6] Bcl-2 and p53 expressions in invasive bladder cancers
    Kong, G
    Shin, KY
    Oh, YH
    Lee, JJ
    Park, HY
    Woo, YN
    Lee, JD
    ACTA ONCOLOGICA, 1998, 37 (7-8) : 715 - 720
  • [7] p53 alterations in human cancers: Basic information and clinical applications
    Silvestrini, R
    EUROPEAN JOURNAL OF CELL BIOLOGY, 1997, 72 : 42 - 42
  • [8] An uncertain role for p53 gene alterations in human prostate cancers
    Brooks, JD
    Bova, GS
    Ewing, CM
    Piantadosi, S
    Carter, BS
    Robinson, JC
    Epstein, JI
    Isaacs, WB
    CANCER RESEARCH, 1996, 56 (16) : 3814 - 3822
  • [9] GENETIC-EVIDENCE IN MELANOMA AND BLADDER CANCERS THAT P16 AND P53 FUNCTION IN SEPARATE PATHWAYS OF TUMOR SUPPRESSION
    GRUIS, NA
    WEAVERFELDHAUS, J
    LIU, QY
    FRYE, C
    EELES, R
    ORLOW, I
    LACOMBE, L
    PONCECASTANEDA, V
    LIANES, P
    LATRES, E
    SKOLNICK, M
    CORDONCARDO, C
    KAMB, A
    AMERICAN JOURNAL OF PATHOLOGY, 1995, 146 (05): : 1199 - 1206
  • [10] Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas
    Goussia, Anna C.
    Papoudou-Bai, Alexandra
    Charchanti, Antonia
    Kitsoulis, Panagiotis
    Kanavaros, Panagiotis
    Kalef-Ezra, John
    Stefanou, Dimitrios
    Agnantis, Niki J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 3985 - 3988